

Lung cancer is the leading cause of cancer death in the U.S. and globally; it is most treatable at its earliest stages.

As lung cancer screening expands, more small peripheral nodules are being detected, many of which remains inaccessible with current bronchoscopic biopsy tools due to device size, limited accuracy, procedural complexity, and high cost.

Together with our partners, we are developing a guidewire-based multi-modality lung biopsy platform, enabling a paradigm shift in minimally-invasive peripheral access, diagnostic yield, procedural simplicity, and cost effectiveness, to advance lung cancer treatment and diagnosis.

